Info

Running Through Walls

Running Through Walls is a Venrock podcast featuring candid conversations between investors and entrepreneurs. Each episode, we offer a behind-the-scenes look at the breakthroughs, challenges and nuttiness associated with building and growing companies. Venture capital firm Venrock has been investing in entrepreneurs across technology and healthcare since 1969.
RSS Feed
Running Through Walls
2024
July
June
May
April
January


2023
December
November
October
September
June
May
March
January


2022
December
November
October
September
August
May
March
February
January


2021
December
October
August
June
May
April
March
February
January


2020
December
November
October
September
August
June
February
January


2019
December
November
August
May
April
January


2018
October
September
June
May
April
March
February
January


2017
December
November
October
July
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May


All Episodes
Archives
Now displaying: 2024
Jul 17, 2024

David Stark, Chief Medical Officer at Morgan Stanley, speaks with Venrock partner Bob Kocher to discuss his career journey from practicing medicine to taking a non-clinical role in business. Stark shares how he views his role as Chief Medical Officer, advice for other doctors who want to transition out of practicing medicine, what he’s proudest of at Morgan Stanley and more.

Jun 26, 2024

Alex Rosemblat, former Chief Marketing Officer at Datadog, speaks with Venrock partner Ethan Batraski to discuss his 11-year run at the helm of Datadog’s Marketing Team and what’s next for his career. Rosemblat shares insights into leading Datadog’s go-to-market strategy, advice for other marketing leaders tackling this for a new product or company for the first time, his biggest learning from Datadog and more. During the conversation, Rosemblat recommended Digital CMO's Guide to Marketing Measurement by Bryan Semple. 


Book mentioned: https://vnrk.co/3VuFvxg 

Jun 12, 2024

Heather Turner, CEO at Carmot Therapeutics, speaks with Venrock partner Nimish Shah to discuss her time as CEO. Turner shares how she guided the company through its acquisition by Roche, advice for other CEOs on the verge of an acquisition, her perspective on the GLP-1 market and what excites her about the future of biotech. 

May 22, 2024

Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.

May 9, 2024

We have a special episode today because Venrock’s 8th annual Healthcare Prognosis results are in! From drugs (e.g., GLP-1s, pricing negotiations) to fundraising and optimism around the equity market to cybersecurity and AI regulations - this year’s survey covers it all. In this episode, partners Bryan Roberts and Bob Kocher sit down to share their perspectives on the most interesting findings.

Apr 17, 2024

Sami Inkinen, founder and CEO of Virta Health, speaks with Venrock partner Bob Kocher to discuss how Virta has evolved since he was on the podcast seven years ago. Inkinen shares how he views the GLP-1 craze, insights on his go-to-market strategy, advice for founders entering the healthcare market, and how Virta uses AI and technology. 

Apr 3, 2024

Latané Conant, Chief Revenue Officer at 6sense, speaks with Venrock partner Brian Ascher to discuss how her previous marketing role prepared her for her promotion to Chief Revenue Officer. Conant shares her approach to keeping product market fit, her opinion on Marketing Qualified Leads (MQLs), how AI could impact sales and marketing and more.

Jan 24, 2024

Isan Chen, CEO of MBrace Therapeutics, speaks with Venrock partner Racquel Bracken to discuss his career trajectory leading up to his founding of MBrace. Chen shares the impetus behind his decision to become an oncologist, why he switched from academic medicine to the industry side, lessons learned from years in drug development and more.

1